{"id":"consolidative-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL2108717","moleculeType":"Cell"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach typically involves using immunotherapy agents (such as PD-1/PD-L1 inhibitors) in a consolidation setting after initial treatment to maintain or amplify anti-tumor immunity. The strategy aims to prevent relapse by sustaining T-cell activation and tumor surveillance in patients who have achieved remission or partial response.","oneSentence":"Consolidative immunotherapy enhances anti-tumor immune responses by combining checkpoint inhibition with additional immune-activating strategies to prevent cancer recurrence.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:28.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer consolidation therapy (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT03391869","phase":"PHASE3","title":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-29","conditions":"Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":339},{"nctId":"NCT06391814","phase":"NA","title":"Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2024-01-16","conditions":"EBV Associated Lymphoma","enrollment":1},{"nctId":"NCT06277388","phase":"","title":"Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-05","conditions":"Non-small Cell Lung Cancer, Cardiac Toxicity","enrollment":231},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT07371247","phase":"EARLY_PHASE1","title":"Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-20","conditions":"Esophageal Cancer, MRD, ctDNA","enrollment":65},{"nctId":"NCT01496976","phase":"PHASE2","title":"Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-03-30","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":45},{"nctId":"NCT04728230","phase":"PHASE1, PHASE2","title":"Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-05","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":63},{"nctId":"NCT06353906","phase":"PHASE2","title":"Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-08-13","conditions":"Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases","enrollment":27},{"nctId":"NCT06529081","phase":"NA","title":"Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Copernicus Memorial Hospital","startDate":"2024-04-01","conditions":"Small Cell Lung Carcinoma","enrollment":165},{"nctId":"NCT06734702","phase":"PHASE3","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":497},{"nctId":"NCT06545747","phase":"PHASE3","title":"Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Non-small Cell Lung Cancer","enrollment":490},{"nctId":"NCT07052669","phase":"PHASE3","title":"Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-01","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":311},{"nctId":"NCT03867175","phase":"PHASE3","title":"Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-06-24","conditions":"Metastatic Lung Cancer, Stage IV Lung Cancer","enrollment":5},{"nctId":"NCT06916117","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-05","conditions":"Locally Advanced Cervical Cancer","enrollment":30},{"nctId":"NCT06114108","phase":"NA","title":"Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2023-12-21","conditions":"Non-small Cell Lung Cancer (NSCLC), Stage IV","enrollment":128},{"nctId":"NCT03043599","phase":"PHASE1, PHASE2","title":"Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-02-13","conditions":"Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT03703050","phase":"PHASE2","title":"Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-01-02","conditions":"Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma","enrollment":45},{"nctId":"NCT05248256","phase":"NA","title":"Vertebral Marrow Attention Trial (VMAT)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-09-29","conditions":"Lung Cancer","enrollment":12},{"nctId":"NCT05552846","phase":"NA","title":"Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2021-01-30","conditions":"Small-cell Lung Cancer","enrollment":104},{"nctId":"NCT06479473","phase":"PHASE1, PHASE2","title":"Radiotherapy to All Residual Lesions After Chemoimmunotherapy","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-06-01","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":150},{"nctId":"NCT04951063","phase":"PHASE1","title":"Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Locally Advanced Lung Carcinoma","enrollment":18},{"nctId":"NCT05951127","phase":"NA","title":"Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-11-01","conditions":"Esophageal Squamous Cell Carcinoma, Oligometastatic Disease","enrollment":141},{"nctId":"NCT01497496","phase":"PHASE2","title":"Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-01-26","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":29},{"nctId":"NCT03087929","phase":"","title":"Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2013-09-20","conditions":"Lymphoma, Follicular","enrollment":12},{"nctId":"NCT03069248","phase":"PHASE2","title":"Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2000-06-01","conditions":"Follicular Lymphoma","enrollment":36},{"nctId":"NCT00005801","phase":"PHASE2","title":"Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"1999-11","conditions":"Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Consolidative immunotherapy","genericName":"Consolidative immunotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Consolidative immunotherapy enhances anti-tumor immune responses by combining checkpoint inhibition with additional immune-activating strategies to prevent cancer recurrence. Used for Cancer consolidation therapy (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}